What is NexImmune, Inc. (NEXI)?

NexImmune, Inc. (NEXI) is a stock in the Healthcare sector, Medical - Pharmaceuticals industry. View full analysis on Stocks360.

What is the current price of NEXI?

The current price of NEXI is $0.00. Prices are updated in real time on Stocks360.

What is NEXI's price-to-earnings (PE) ratio?

NEXI's trailing twelve-month PE ratio is -0.00, based on current price and earnings per share data available on Stocks360.

What is NEXI's market capitalization?

NEXI's market capitalization is $139.00, placing it in the small-cap tier.

NexImmune, Inc. (NEXI)

Stock analysis · OTC · Healthcare · Medical - Pharmaceuticals

$0.00

Market Cap

$139.00

PE (TTM)

-0.00

EPS (TTM)

N/A

Dividend Yield

0.00%

Beta

4.05

Day Range

$0.00 – $0.00

52-wk Range

$0.00 – $0.00

Avg Volume

N/A

Volume

100.00

NexImmune, Inc. (NEXI) is a publicly traded company in the Healthcare sector. Latest price: $0.00. Market cap $139.00. Trailing PE -0.00. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

You have viewed 9 SEO analysis pages

Unlock saved watchlists, personalized setups, and referral credits with a free Stocks360 account.

Continue with free signup

1-Year Price

2025-10-31 · $0.00 2026-10-28 · $0.00 (+0.00%)

Earnings

Most Recent

Aug 7, 2024

EPS $-1.69 vs est. $-7.25

Beat by $5.56

Next Earnings

Nov 17, 2026

EPS estimate $-13.25

Proprietary Signals

Signal snapshot temporarily unavailable.

About NexImmune, Inc.

NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases in the United States. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a vivo directly injectable modality platform. The company’s product candidates include NEXI-001, an allogeneic cell therapy, which is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia; NEXI-002, an autologous cell therapy that is in Phase I/II clinical trials for the treatment of patients with relapsed and/or refractory in multiple myeloma; and NEXI-003, a product candidate targeted against HPV related cancers, which is in Phase I/II clinical trials. It also provides NEXI-004 which is in preclinical stage for EBV related diseases. NexImmune, Inc. was incorporated in 2011 and is headquartered in Gaithersburg, Maryland.

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	-0.00×
P/S (TTM)	0.00×
P/B	0.00×
P/FCF (TTM)	-0.00×
EV / EBITDA	0.11×
EV / Sales	0.00×
Earnings Yield	-30819798.22%
Free Cash Flow Yield	-22646846.04%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	-$3.13M
Net Income (TTM)	-$42.84M
Free Cash Flow (TTM)	-$31.48M
Net Debt	-$3.13M
Working Capital	$316.73K
Gross Margin	0.00%
Operating Margin	0.00%
Net Margin	0.00%
Return on Equity	-180.64%
Return on Invested Capital	-815.77%